Ibrutinib

Ibrutinib is an oral medication that belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. It is specifically used to treat certain types of cancer, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The drug works by blocking the action of BTK, which is an enzyme that plays a crucial role in the growth and spread of these cancerous cells. By inhibiting BTK, Ibrutinib helps to reduce the production and spread of cancer cells, thus alleviating symptoms and potentially increasing the survival rate of patients.